Cascadian Therapeutics (CASC)

[tedkov]

Cascadian Shareholders Upset Over Merger Bid - (via NewsPoints Desk)
January 31, 2018
Tags: NewsPoints Cascadian Seattle Genetics United States Corporate Affairs Mergers &
Acquisitions

A group of Cascadian Therapeutics Inc. shareholders are attempting
to block the $300 million purchase of the company by Seattle Genetics.

The shareholders allege that the purchase price of $10 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. Indeed the company has over $100 million of cash on its balance sheet or $2 cash per share and no debt. In addition, shareholders allege that senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.

Cascadian did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Cascadian for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or [e-mail]

[mudcat61820]

SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation to tucatinib for the treatment of HER2-positive (HER2+) metastatic colorectal cancer. Tucatinib is an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and is the Company’s lead product in development.

[Panzer]

Management team can burn in hell as far as I'm concerned

[Zemo]

Guess that 6 to 1 reverse split to get institutional investments involved (only way to ORCHESTRATE a share price above $5) SLIGHTLY BACKFIRED & was very short lived. Hanging at $3.88 today, or .65 cents to us ex-bagholders! Nitwit Board of Directors. Complete farce of an organization top to bottom. Red Plate, Mainly Lobster must be PROUD... Washington democrats... all 'upstanding', lieing, ripoff, sanctuary snowflakes! CASC/ONTY absolutely destroyed shareholders... who will NEVER recover.

[Panzer]

Back in CASC looking for double boom

[snupoled]

back in at 5.54 Lets see if there is a flip
left in casc for next week.

snup dawg oled

[snupoled]

nice coin,

got out 642-6.68

sweet,

looking to do this again as interest should re-new
for friday presentation 7:30-9am pre market yowza

snupdawgoled

[snupoled]

excuse me Snupdawg casc has news that you thought would be
released pre-market on Friday, snup you are so right
it is impossible to time the market with exact precision
but your recent buys are looking

$$$$$$$$$$$$$$$$$

snupdawgoled relishing the moment

[snupoled]

nice swing back up yesterday a leak? no volume was low

but nice to see us back at a buck pre split.

hopefully we get a surge pre market on friday

snupdawgoled

[snupoled]

symposium,

we present after 5pm tomorrow wed
thursday may start to get a vibe

friday presentation on 1b trial 7:30 -9am pre market

casc about to rock?

or

re-newed selling?

to be continued

[snupoled]

quite a see saw of pps

let's see if symposium wed-fri

will be nice catalyst for casc's inflection upwards


super whale bought huge at 92 cent level or 5.72 cent levels

snupdawgold

[snupoled]

well a new day

still awaiting shortie to return with hammer today

after they suck in new buyers like yesterday,

hopefully,

we get some good news later next week

we present I believe on dec 6 and 7

next friday presentation is 730-9 am

of course I am looking for decisive pop friday and following
week on adventagious data.

snup

[snupoled]

Man, I am being brought to the wood shed by casc shorties

today, You guys are blls to the metal, wow!

snup

[snupoled]

You thought that was bad 5.04 low for the day,

man , I am on the wrong side of this stock.

They are shorting casc with abandon, hopefully my

hunch is right and they have good news coming from

symposium dec.5-7 to quiet the nerves of longs

snup

[snupoled]

93 cents pre rs or 5.60 a share ouch

92 cents was where whale bought at

conference dec.5-7

snup

[snupoled]

5.83 holding steady near .97 cents pre split

we got the symposium next wed thru friday

should be inflection point.

snupdawgoled

[snupoled]

last day to get out pre rs

I think we get go up after symposiom dec 5-8

casc about to start attracting main stream investors

after 1:6 rs

snup

[snupoled]

rs on tues morning same symbol

bought 24k more today, I think dec 6 and 7 symposium will
yield good news and with volatility of rs 1:6 it could yield
a couple of bucks movement to the upside.

casc has a 52 week high of 3 plus
a major purchase by a whale at 92 cents

play the ball where it is 1.03

snup dawg oled

[snupoled]

Jnizz,

picked up a few today, rs before dec.31 52-week low 82
high about 1.81 seems like a great entry point.

around dec.5 reveals more data on lead drug Tan

looking for a bounce up on healthy volume pre-meeting
in sandiego, will decide then to hold thru split or not
if data still awesome.

snup

[Panzer]

They will be announcing between a 5-11 to 1 split I believe. I say go for the 11 lol

[harmsen]

When is are a split?

[Panzer]

All bios down casc especially hit I'm buying

[WAM2]

What is happening here?!?!?

[Jnizz]

Doesn't make much sense... even with good results the price drops. They are using the reverse split to get more institutional support so I don't understand what all the selling off is about?

[Fist Full of Dollars]

Reverse split

[WAM2]

What is happening here. Great results so why does the stock price keep dropping?

[Panzer]

Buying CASC here

[W&T Capital LLC]

Can anyone tell me please if Monday's poster presentations are old news or new data not seen? I'm not sure of conference policy?

[Panzer]

Agree great hold through EOY

[stocktrademan]

CASC bullish 1.725



normal chart


log chart

[realnewb]

Very nice. I bought 1000 shares when they relisted as Casc. Riding a little less then half of that now as freebies after the past few days.

This thing is gonna push 2-2.25 in the near future. Whoever bought 2 million shares the past few days is probably holding. Should move up quickly on any news about phase 2s.

Go onty oops I mean Casc lol

[Panzer]

Reloading big with dip

[Panzer]

Just trimmed 50% of position profits here

[realnewb]

CASC formerly ONTY up over 20%
4x volume yesterday NO NEWS

Looks like a hedge is buying it up!

[realnewb]

Casc up big on huge EOD and after hour trading!

[realnewb]

Where is everybody!? There's a long run ahead!

[stocktrademan]

CASC bullish 1.17

[venturecapp]

This Investor Just Grabbed 25 Million Shares Of Cascadian Therapeutics

http://marketexclusive.com/investor-grabs-25-million-shares-cascadian-therapeutics-inc-usa-nasdaqcasc/9003/?icd1

[Green_Goblin]

CASC looking good going into Monday. Great ah action on Friday.

[aries4747]

CASC: Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer

Jun 29, 2016 08:00:00 (ET)

Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer

SEATTLE, June 29, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug Administration ("FDA").

The Company is actively recruiting patients for a randomized, double-blind, placebo-controlled Phase 2 study, known as HER2CLIMB, evaluating ONT-380 in combination with trastuzumab and capecitabine for patients with advanced HER2+ metastatic breast cancer. This trial is expected to enroll up to 180 patients with and without brain metastases. ONT-380 is an oral, highly selective small molecule inhibitor of HER2.

"Fast Track designation recognizes the unmet medical need for this serious disease," said Scott Myers, President and CEO of Cascadian Therapeutics. "Many patients with metastatic HER2+ breast cancer will see their disease progress despite the availability and use of multiple targeted therapies. We are encouraged by the early evidence of systemic activity and activity against brain metastases, and the favorable tolerability profile with ONT-380 in combination studies."

The FDA established the Fast Track designation process to facilitate development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Through the Fast Track program, more frequent meetings may be scheduled with the FDA to discuss the drug's development plan and to ensure the collection of appropriate data needed to support approval. Additionally, the drug may qualify for accelerated approval and priority review and, at the time of a new drug application (NDA) filing, the drug candidate's sponsor may be eligible to submit completed sections of the NDA on a rolling basis before the complete application is submitted.

"Fast Track designation has the potential to reduce development time and cost associated with bringing a drug to patients," said Valerie Fauvelle, Director of Regulatory Affairs for Cascadian Therapeutics. "We look forward to working closely with the FDA to rapidly advance ONT-380 through the clinical development and regulatory process."

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Our lead product candidate, ONT-380, is an orally active and selective small molecule HER2 inhibitor, which has been studied in approximately 200 patients to date. Preliminary results from two ongoing Phase 1b studies of ONT-380 in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian is also conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB (ONT-380 + trastuzumab + capecitabine) in patients with locally advanced or metastatic HER2+ breast cancer previously treated with a taxane, trastuzumab, pertuzumab, and T-DM1. This study is expected to enroll 180 patients with and without brain metastases across approximately 100 clinical sites in the U.S., Canada, and Western Europe. For more information, visit www.ClinicalTrials.gov: NCT02614794. The Company is also developing a cell cycle inhibitor, Chk1, and plans to move the program forward through IND-enabling studies in 2017.

Forward-Looking Statements

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, timing of additional data and potential benefits of its product candidates.

Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Except as required by law, Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Cascadian Therapeutics can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

Investor Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
[e-mail]

Tricia Truehart
The Trout Group
646-378-2953
[e-mail]

Media Contact:
Amy Bonanno
BMC Communications
646-513-3117
[e-mail]

(MORE TO FOLLOW) Dow Jones Newswires

June 29, 2016 08:00 ET (12:00 GMT)

[aries4747]

CASC: Cascadian Therapeutics Has Gross Proceeds of $32.2M From Exercise of Over-Allotment Option

Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock

SEATTLE, June 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it has closed the previously announced underwritten public offering of 40,250,000 shares of its common stock at a price to the public of $0.80 per share for gross proceeds of $32.2 million. The shares include 5,250,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full. In addition, Cascadian Therapeutics closed the previously announced offering of 17,250 shares of its Series D Convertible Preferred Stock at a price of $800.00 per share directly to affiliates of BVF Partners L.P., which are existing stockholders and affiliates of a member of the board of directors of Cascadian Therapeutics, for gross proceeds of $13.8 million.

Aggregate gross proceeds from both offerings, before deducting underwriting and placement agent discounts and commissions and expenses, was $46.0 million. The offerings were conducted as separate offerings by means of separate prospectus supplements, and neither the sale of Series D Convertible Preferred Stock nor the common stock offering was contingent upon the consummation of the other.

Each share of Series D Convertible Preferred Stock is non-voting and convertible into 1,000 shares of Cascadian Therapeutics common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 19.99% of the common stock then outstanding, subject to adjustment. The Series D Convertible Preferred Stock will rank senior to all of the company's common stock, on parity with the Company's Series A, B and C Convertible Preferred Stock and junior to the Company's Class UA Preferred Stock. In the event of a liquidation, dissolution or winding up of the Company, holders of the Series D Convertible Preferred Stock will receive a payment equal to $0.0001 per share of Series D Convertible Preferred Stock before any proceeds are distributed to the holders of the common stock, pari passu with any distribution of proceeds to holders of the Series A, B and C Convertible Preferred Stock, and after any distribution of proceeds to holders of the Class UA Preferred Stock.

Cowen and Company, LLC acted as the sole book-running manager and Trout Capital LLC acted as a co-manager in the common stock offering. Cowen and Company, LLC and Trout Capital LLC acted as the placement agents in the registered direct offering.

Each of the offerings was made to purchasers pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission, or SEC. Prospectus supplements and accompanying prospectuses describing the terms of the offerings are filed with the SEC. Copies of the prospectus supplements and accompanying prospectuses may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling [phone]. Electronic copies of the prospectus supplements and accompanying prospectuses will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of Cascadian Therapeutics, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investor and Media Relations Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
[e-mail]

(MORE TO FOLLOW) Dow Jones Newswires

June 28, 2016 16:01 ET (20:01 GMT)

Jun 28, 2016 16:01:00 (ET)

[casinoo]

Likely futile U.K. petition for 2nd Brexit referendum tops 2 million http://on.mktw.net/28Vk27E

[parrishilton]

they can do both or either or for casc

[parrishilton]

yes finally came out casc

[parrishilton]

casc needs some good news soon

[parrishilton]

not sure if this is good or bad new name casc

[dave86]

This is taking a beating today.

[croptop]

thx
no mods for this board it seems

[4on4off]

Board Moderators request the change:

How do I get a board name/symbol changed?

If you are the board's Moderator or an Assistant you can go to the Manage page and click Board Name/Ticker Change and fill in the requested information. These go into a queue that are reviewed by site Admins throughout the day.

Since there are no current Mods I contacted Admin to address the change.

CASC

[croptop]

Do Mods change symbol or start a new board?